{"id":3878,"date":"2024-05-11T22:23:41","date_gmt":"2024-05-11T14:23:41","guid":{"rendered":"https:\/\/flcube.com\/?p=3878"},"modified":"2025-02-08T12:55:04","modified_gmt":"2025-02-08T04:55:04","slug":"tianjin-lisheng-pharmaceutical-co-ltd-to-sell-stake-in-mitsubishi-tanabes-china-subsidiary","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=3878","title":{"rendered":"Tianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe’s China Subsidiary"},"content":{"rendered":"\n

Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393<\/a>), a Chinese pharmaceutical company, has announced plans to sell its 24.65% stake in the Tianjin subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation. The assessed value of all shareholder equity, calculated using the income method, is RMB 486 million (USD 67.3 million), marking an appreciation of RMB 299.1 million or 160.03%.<\/p>\n\n\n\n

The Tianjin subsidiary is a core part of Mitsubishi Tanabe’s operations in China, specializing in the manufacturing and marketing of originator drugs for chronic diseases such as cardiovascular, cerebrovascular, endocrine metabolism, and gastrointestinal disorders. Mitsubishi Tanabe supplies raw materials and some formulation products, which are then produced, repackaged, and sold locally by the Tianjin unit. Key products including Herbesser (diltiazem), Herbesser capsules (diltiazem), Anplag (sarpogrelate), Tanatril (imidapril), and Cerekinon (trimebutine) are manufactured, packaged, and sold by the subsidiary. Additionally, Herbesser injection, Novastan (argatroban), and Tenelia (teneligliptin) are produced by the parent company and sold by the unit after local packaging.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), a Chinese pharmaceutical company, has announced plans to…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[806,2636,1544],"class_list":["post-3878","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-lisheng-pharmaceutical","tag-mitsubishi-tanabe-pharma-corporation","tag-she-002393"],"yoast_head":"\nTianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe's China Subsidiary - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), a Chinese pharmaceutical company, has announced plans to sell its 24.65% stake in the Tianjin subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation. The assessed value of all shareholder equity, calculated using the income method, is RMB 486 million (USD 67.3 million), marking an appreciation of RMB 299.1 million or 160.03%.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=3878\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe's China Subsidiary\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=3878\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-11T14:23:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-08T04:55:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3878#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3878\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Tianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe’s China Subsidiary\",\"datePublished\":\"2024-05-11T14:23:41+00:00\",\"dateModified\":\"2025-02-08T04:55:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3878\"},\"wordCount\":170,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Lisheng Pharmaceutical\",\"Mitsubishi Tanabe Pharma Corporation\",\"SHE: 002393\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=3878#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3878\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=3878\",\"name\":\"Tianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe's China Subsidiary - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-05-11T14:23:41+00:00\",\"dateModified\":\"2025-02-08T04:55:04+00:00\",\"description\":\"Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), a Chinese pharmaceutical company, has announced plans to sell its 24.65% stake in the Tianjin subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation. The assessed value of all shareholder equity, calculated using the income method, is RMB 486 million (USD 67.3 million), marking an appreciation of RMB 299.1 million or 160.03%.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3878#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=3878\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3878#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe’s China Subsidiary\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe's China Subsidiary - Insight, China's Pharmaceutical Industry","description":"Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), a Chinese pharmaceutical company, has announced plans to sell its 24.65% stake in the Tianjin subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation. The assessed value of all shareholder equity, calculated using the income method, is RMB 486 million (USD 67.3 million), marking an appreciation of RMB 299.1 million or 160.03%.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=3878","og_locale":"en_US","og_type":"article","og_title":"Tianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe's China Subsidiary","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=3878","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-05-11T14:23:41+00:00","article_modified_time":"2025-02-08T04:55:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=3878#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=3878"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Tianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe’s China Subsidiary","datePublished":"2024-05-11T14:23:41+00:00","dateModified":"2025-02-08T04:55:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=3878"},"wordCount":170,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Lisheng Pharmaceutical","Mitsubishi Tanabe Pharma Corporation","SHE: 002393"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=3878#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=3878","url":"https:\/\/flcube.com\/?p=3878","name":"Tianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe's China Subsidiary - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-05-11T14:23:41+00:00","dateModified":"2025-02-08T04:55:04+00:00","description":"Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), a Chinese pharmaceutical company, has announced plans to sell its 24.65% stake in the Tianjin subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation. The assessed value of all shareholder equity, calculated using the income method, is RMB 486 million (USD 67.3 million), marking an appreciation of RMB 299.1 million or 160.03%.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=3878#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=3878"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=3878#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Tianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe’s China Subsidiary"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3878"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3878\/revisions"}],"predecessor-version":[{"id":25871,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3878\/revisions\/25871"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}